Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$241,735

38 payments

Through program year 2025, Advanced Clinical Research Center is reported as receiving $241,735 in research payments, across 38 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $209,356 30
2024 Research $18,830 7
2023 Research $13,550 1

Breakdown

Who paid Research payments · program years 2023–2025
  1. Mesoblast, Inc. $99,601 9 payments
  2. AbbVie, Inc. $71,846 24 payments
  3. AstraZeneca Pharmaceuticals LP $64,221 4 payments
  4. AstraZeneca UK Limited $6,067 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. Msb-Dr004 $99,601 9 payments
  2. A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis $63,781 3 payments
  3. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $21,676 7 payments
  4. A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis $14,024 1 payment
  5. M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $14,000 1 payment
  6. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $12,280 10 payments
  7. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $6,323 1 payment
  8. A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus $6,067 1 payment
  9. M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $2,242 3 payments
  10. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $1,301 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record